InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Proposed issue of Securities - MXC 10 Sep 2020 10:08AM $0.024 $0.420 risen by 1,650%
$18 $15M FINANCE FACILITY TO FUND REVENUE GROWTH FOR KEY MARKETS 10 Sep 2020 10:07AM $0.024 $0.420 risen by 1,650%
$18 Trading Halt 8 Sep 2020 9:47AM $0.024 $0.420 risen by 1,650%
$18 Initial Director's Interest Notice - Appx 3X - Evan Hayes 4 Sep 2020 11:51AM $0.024 $0.420 risen by 1,650%
$18 BIOPHARMA APPOINTMENTS STRENGTHEN BOARD AND LEADERSHIP TEAM 1 Sep 2020 8:05AM $0.025 $0.420 risen by 1,580%
$18 Appendix 4E and Preliminary Unaudited Financial Report 31 Aug 2020 5:28PM $0.025 $0.420 risen by 1,580%
$18 JV TO BE ESTABLISHED FOR REGISTRATION OF ARTEMIC IN RUSSIA 25 Aug 2020 9:28AM $0.027 $0.420 risen by 1,455.56%
$18 COVID-19 Interim Trial Results Meet All Primary Objectives 20 Aug 2020 11:29AM $0.026 $0.420 risen by 1,515.38%
$18 Trading Halt 19 Aug 2020 9:28AM $0.026 $0.420 risen by 1,515.38%
$18 UK DISTRIBUTION AGREEMENT SIGNED FOR MGC PHARMA MEDICINES 14 Aug 2020 10:07AM $0.024 $0.420 risen by 1,650%
$18 Change of Director's Interest Notice - Appendix 3Y x 2 13 Aug 2020 11:01AM $0.024 $0.420 risen by 1,650%
$18 Prospectus 12 Aug 2020 4:56PM $0.024 $0.420 risen by 1,650%
$18 Issue of Securities 12 Aug 2020 4:55PM $0.024 $0.420 risen by 1,650%
$18 Issue of Securities - Appendix 2A 12 Aug 2020 4:42PM $0.024 $0.420 risen by 1,650%
$18 Proposed issue of Securities - MXC 12 Aug 2020 3:16PM $0.025 $0.420 risen by 1,580%
$18 STUDY CONFIRMS EFFECTIVENESS OF ARTEMIC ON HUMAN IMMUNE CELL 7 Aug 2020 9:38AM $0.022 $0.420 risen by 1,809.09%
$18 Trading halt 5 Aug 2020 10:15AM $0.022 $0.420 risen by 1,809.09%
$18 Pause in trading 5 Aug 2020 9:52AM $0.022 $0.420 risen by 1,809.09%
$18 Appendix 2A - Exercise of MXCOE Options 31 Jul 2020 4:26PM $0.021 $0.420 risen by 1,900%
$18 June Quarterly Activity and Cashflow Report 31 Jul 2020 1:36PM $0.023 $0.420 risen by 1,726.09%
$18 Reinstatement to Official Quotation 27 Jul 2020 9:23AM $0.024 $0.420 risen by 1,650%
$18 Results from ArtemiC Safety and Toxicity Pre-clinical Study 27 Jul 2020 9:21AM $0.024 $0.420 risen by 1,650%
$18 Suspension from Official Quotation 24 Jul 2020 9:50AM $0.024 $0.420 risen by 1,650%
$18 Trading Halt 22 Jul 2020 10:14AM $0.024 $0.420 risen by 1,650%
$18 Pause in Trading 22 Jul 2020 9:54AM $0.024 $0.420 risen by 1,650%

401 - 425 of 818 results

Page 17 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.